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Abstract: Glycosylation of polyphenols may increase their aqueous solubility, stability, bioavailability and
pharmacological activity. Herein, we used a mutant of sucrose phosphorylase from Thermoanaerobacterium
thermosaccharolyticum engineered to accept large polyphenols (variant TtSPP_R134A) to produce phloretin
glucosides. The reaction was performed using 10% (v/v) acetone as cosolvent. The selective formation of a
monoglucoside or a diglucoside (53% and 73% maximum conversion percentage, respectively) can be
kinetically controlled. MS and 2D-NMR determined that the monoglucoside was phloretin 4’-O-α-D-
glucopyranoside and the diglucoside phloretin-4’-O-[α-D-glucopyranosyl-(1!3)-O-α-D-glucopyranoside], a
novel compound. The molecular features that determine the specificity of this enzyme for 4’-OH phenolic
group were analysed by induced-fit docking analysis of each putative derivative, using the crystal structure of
TtSPP and changing the mutated residue. The mono- and diglucoside were, respectively, 71- and 1200-fold
more soluble in water than phloretin at room temperature. The α-glucosylation decreased the antioxidant
capacity of phloretin, measured by DPPH and ABTS assays; however, this loss was moderate and the activity
could be recovered upon deglycosylation in vivo. Since phloretin attracts a great interest in dermocosmetic
applications, we analyzed the percutaneous absorption of glucosides and the aglycon employing a pig skin
model. Although the three compounds were detected in all skin layers (except the fluid receptor), the
diglucoside was present mainly on superficial layers.
Keywords: Phloretin; enzymatic glycosylation; polyphenol bioavailability; glucosides; skin absorption; glycoside
phosphorylases
RESEARCH ARTICLE DOI: 10.1002/adsc.202100201
Adv. Synth. Catal. 2021, 363, 1–12 © 2021 The Authors. Advanced Synthesis & Catalysis
published by Wiley-VCH GmbH
1
These are not the final page numbers! ��
Wiley VCH Donnerstag, 06.05.2021
2199 / 203419 [S. 1/12] 1
Introduction
Living organisms are continually subjected to endoge-
nous and exogenous oxidants that can damage their
biomolecules such as DNA, lipids and proteins. These
oxidative physiological processes can derive in disor-
ders like cancer, Alzheimer disease, Parkinson disease,
arthritis, cardiovascular problems or inflammation.[1]
Even at low concentrations, antioxidants can inactivate
intracellular Reactive Oxygen Species (ROS) and other
free radicals.[2] Among them, plant polyphenols have
demonstrated a notable efficiency against these
disorders.[3]
Phloretin (2’,4’,6’-trihydroxy-3-(4-hydroxyphenyl)-
propiophenone) is a dihydrochalcone mainly present in
most parts of apple trees – including the skin and
pomace of apples –,[4] which possesses a notable
antioxidant activity and stands out for a variety of
biological properties. Thus, it displays an inhibitory
effect on the active transport of glucose,[5] which
makes it an interesting compound as antidiabetic.
Hsiao et al. demonstrated the phloretin capacity to
suppress cancer cells invasion and migration, acting as
a potential anticancer assistant combined with other
current treatments.[6] The inhibition of a HIV-1 trans-
membrane protein by phloretin and its β-glucoside
derivative trilobatin was also reported.[7]
The low aqueous solubility of phloretin (<0.2 mM)
constrains its applications in functional food and
pharmaceutical industries.[8] This fact is well related to
its low bioavailability, manifested in a low oral
absorption, fast metabolism, and rapid elimination in
the urine and feces.[9] Apart from pharmaceutical
strategies (formation of complexes with cyclodextrins,
nanosuspensions, etc.) or absorption boosters,[10] the
modification of the structure of polyphenols by
glycosylation is an excellent way to increase their
hydrophilicity and stability, leading to an improved
bioavailability and better pharmacological activity.[11]
In nature, we can find many polyphenol glycosides,
e. g. bearing a glucose, rhamnose or arabinose
residue.[12] The sugar moiety can play an important role
in intestinal absorption[13] and bioavailability.[14] Fur-
thermore, the glycosylation of polyphenols can modu-
late their pharmacokinetic properties, stability and
solubility in comparison with the aglycon.[15]
To obtain polyphenol glycosides, the use of
enzymes offers several advantages over chemical
processes.[16] Glycosyl hydrolases (GHs)[17] can serve
that purpose but typically offer low yields of glycosy-
lated derivatives.[18] Transglycosidases (TGs) display a
higher transfer to hydrolysis ratio and employ cheap
donor substrates such as sucrose or maltodextrins.[16,19]
Glycosyltransferases (GTs) offer the highest yields by
far, but they require expensive nucleotide-activated
sugar donors.[20]
In this context, glycoside phosphorylases have
attracted increasing attention as biocatalysts for glyco-
syl transfer.[21] In vivo, they catalyze the degradation of
di- and oligosaccharides with inorganic phosphate, but
the reaction is readily reversible in vitro due to the
high energy content of the synthesized glycosyl
phosphate.[22] Interestingly, sucrose phosphorylases
(SPs) can also be used as transglycosidases as they are
able to transfer the glucosyl unit of sucrose to different
acceptors such as oligosaccharides, phenolic deriva-
tives or alkyl glucosides.[23] Nevertheless, the activity
of SPs using bulky phenolic compounds as acceptors is
rather limited.
Several enzyme engineering strategies have been
developed to increase the acceptor specificity of
glycosidic enzymes for large polyphenolic compounds,
including SPs and related enzymes.[15b,24] Dirks-Hof-
meister et al. reported the R134A mutant of sucrose 6’-
phophate phosphorylase from Thermoanaerobacterium
thermosaccharoliticum (TtSPP_R134A),[25] which ex-
hibits higher affinity for polyphenols than the native
enzyme, caused by the increased size of the catalytic
pocket. The mutant was active towards more than 80%
of the phenolic compounds assayed as glucose accept-
ors, including the bulkiest phenolics.[25] In particular, it
was effective for the glucosylation of a variety of
polyphenols such as pyrogallol, methyl gallate, ethyl
gallate, propyl gallate, lauryl gallate, resveratrol,
quercetin, catechin or epicatechin.[26]
In the present work, we report the synthesis of
phloretin glucosides using the sucrose phosphorylase
mutant TtSPP_R134A. The products were chemically
characterized and some of their properties (antioxidant
activity, solubility, etc.) assayed in comparison with
the aglycon. In particular, the effect of glucosylation
on skin absorption was studied since one of the current




Phloretin glucosylation was investigated using the
R134A mutant of the sucrose 6’-phosphate phosphor-
ylase from T. thermosaccharoliticum (TtSPP_R134A).
The reaction was carried out in 50 mM MOPS buffer
(pH 6.5) containing 10% (v/v) acetone to increase the
phloretin solubility, using an excess of sucrose (1 M)
with regard to polyphenol (5 mg/mL).
The reaction was followed by Thin Layer Chroma-
tography (TLC). Two new spots appeared on the TLC
plate, which could correspond to glucosylated deriva-
tives. The formation of three products was observed by
HPLC (Figure 1): one major peak (Glc-Phloretin-1)
and two minor peaks (Glc-Phloretin-2 and -3). How-
ever, the concentration of Glc-Phloretin-2 became
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significant at the latter stages of the reaction, in
contrast with Glc-Phloretin-3.
The progress of the formation of the two main
reaction products was determined (Figure 2). As
shown, the synthesis of the first product (Glc-Phlor-
etin-1) reaches its maximum (4.2 mg/mL, 53% con-
version yield) after approximately 12 h (the remaining
phloretin is almost negligible at that time), and then it
decreases with time alongside the appearance of the
second product (Glc-Phloretin-2). The concentration of
this second product stabilizes at about 8 mg/mL (73%
conversion yield). The conversion of phloretin into its
glucosides is really efficient compared with similar
glucosylations of related polyphenols catalyzed by
GHs and TGs, in which the reported conversion yields
are substantially lower.[12,28]
Most of the glycosylation studies on phloretin have
been carried out with GTs employing UDP-sugar
donors, yielding the C-glucoside nothofagin[29] or the
β-glucoside at 2’-OH phlori(d)zin.[30] To our knowl-
edge, the only work on phloretin glucosylation using
GHs was performed by Overwin et al. using the
amylosucrase from Neisseria polysaccharea.[31] Start-
ing from 10 mM phloretin (half of the concentration
employed in the present work), they synthesized a
mixture of a mono-, di- and tri-glucoside with
conversion efficiency of 35%, 32% and 28%, respec-
tively. However, the process described herein catalyzed
by the mutant TtSPP_R134A allows directing the
reaction selectively to the mono- or the di-glucoside
(Figure 2).
Characterization of Glucosides
The reaction was scaled up to 20 mL and the main
products were purified by silica gel chromatography as
described in the Experimental Section. Both products
(Glc-Phloretin-1 and Glc-Phloretin-2) were character-
ized by ESI-MS and NMR.
Their molecular weights were determined by ESI-
MS coupled to a QTOF analyzer in positive mode. For
Glc-Phloretin-1 we observed the presence of a major
peak with m/z 459.1264 that corresponded to the ion
[M+Na]+ of the monoglucoside (Figure S1, Supple-
mentary Material). In the case of Glc-Phloretin-2, we
observed the major peak with m/z of 621.1787, which
fitted with the [M+Na]+ ion of the diglucoside
(Figure S2, Supplementary Material).
The glucosylation position of the monoglucoside
sample (Glc-Phoretin-1) was determined by NMR. 1D-
selective TOCSY and NOESY experiments, comple-
mented by 2D-HSQC and 2D-HMBC spectra, were
performed to identify and assign the signals. Two
similar compounds were detected in the mixture in a
1:13 ratio. Both compounds exhibit an anomeric proton
with J=3.7 Hz, indicative of an α linkage. For the
major compound, the anomeric H1’’ of glucose
showed NOE correlation with 3’-H and 5’-H aromatic
protons of B ring (Figures S3-A and S3-B, Supplemen-
tary Material), which demonstrated α-glucosylation at
4’-O position of such ring. This arrangement was also
confirmed by a HMBC correlation connecting Glc-
H1’’ to C4’. Therefore, the structure of the major
glucoside 1 is represented in Figure 3. The same
glucoside structure has been reported by Overwin et al.
using the amylosucrase from Neisseria
polysaccharea.[31]
In contrast, for the minor compound (8%), the
corresponding anomeric proton H1’’ showed NOE
Figure 1. HPLC chromatogram of the phloretin glucosylation
reaction at 48 °C after 0 h, 1 h and 24 h. Reaction conditions:
phloretin (5 mg/mL), sucrose (342 mg/mL), MOPS buffer
(50 mM, pH 5.6), acetone (10% v/v) and TtSPP_R134A (5 U/
mL).
Figure 2. Kinetics of the formation at 48 °C of the two
characterized phloretin glucosides. Reaction conditions: phlor-
etin (5 mg/mL), sucrose (342 mg/mL), MOPS buffer (50 mM,
pH 5.6), acetone (10% v/v) and TtSPP_R134A (5 U/mL).
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correlation with one of the aromatic protons of the ring
A, indicating that, in this case, glucosylation took place
at position 4-OH of this ring (Figure S3-B, Supplemen-
tary Material).
With respect to the diglucoside fraction (Glc-
Phloretin-2), the NMR spectra revealed a more
complex mixture of products. The major one displayed
two anomeric signals (H1’’ and H1’’’) with similar J
coupling values, ca. 3.7 Hz (corresponding to α-Glc
linkages). The 1H signals for these two Glc residues
could be determined by using COSY and 1D-selective
TOCSY experiments. The connectivity of these resi-
dues was determined by using 1D-selective ROESY
experiments, which showed NOE correlation between
H1’’ α-Glc and ring B. The other Glc moiety showed
NOE between H1’’’ and H3’’ of the Glc unit linked to
the phloretin moiety (Figure S4, Supplementary Mate-
rial). This H3’’ correlates in the 1H-13 C HSQC
spectrum with a 13C signal at δ 84.3 ppm, typical for a
glycosidation position (Figure S5, Supplementary Ma-
terial). Thus, the proposed structure for compound 2 is
phloretin 4’-O-[α-D-glucopyranosyl-(1!3)-O-α-D-
glucopyranoside], which is also represented in Fig-
ure 3.
To the best of our knowledge, the diglucoside 2 is a
novel compound. In fact, for the diglucoside reported
by Overwin et al. with amylosucrase, the glucoses
were α(1!4) linked. The main properties of the two
synthesized derivatives are summarized in the Exper-
imental Section.
Docking Analysis of TtSPP_R134A Structure in
Complex with Different Phloretin Monoglycosy-
lated Products
We tried to decipher the molecular features that
determine the outstanding specificity of mutant
TtSPP_R134A to α-glucosylate the 4’-OH of phloretin,
which could be useful to modulate the enzyme
specificity by enzyme engineering tools.[32] We per-
formed induced-fit docking analysis of each putative
derivative using as template the crystal structure of
TtSPP after modelling the Arg134 to Ala replacement
(considering the PDB sequence with 14 residues long
N-terminal polyhistidine-tag, Arg134 corresponds to
Arg148 in the deposited coordinates). Thus, three
different phloretin monoglycosylated ligands were
built considering the glycosylation to occur at para-
and ortho- positions in the triphenolic ring, or at the
phenolic hydroxyl group.
The first run of docking analysis using Autodock
4.2[33] revealed that the best results were obtained for
the p-glucosylated compound at the triphenolic ring, in
which near half of the calculated conformations (with-
in 2.0 Å root mean square) converged in the minimum
binding energy of   7.5 kcal/mol (Figure S6, Supple-
mentary Material), whilst the two other derivatives
gave more dispersed solutions among less populated
clusters, with minimum binding energies of   4 and
  6.5 kcal/mol, respectively. This observation was in
accordance with the fact that the 4’- derivative was the
main glucosylated product determined by NMR.
To go deeper into molecular interactions that
govern the specificity of this reaction, AutoDock Vina
was used to explore different modelling approaches.[34]
In order to improve the accuracy of the docking
method, Phe146, Phe171, Tyr215, Glu252, His358,
which are delineating the catalytic tunnel and are
therefore key residues in acceptor-substrate binding,
were defined as flexible side chain residues. Around
20 solutions were calculated in a binding energy range
between   12.6 and   11.6 kcal/mol. From these, con-
formers were selected based on their minimum energy
and more conservative interactions at subsite   1
(Figure 4A), which was checked by comparison to the
reported complex of the homologous Bifidobacterium
adolescentis sucrose phosphorylase with sucrose
(BaSP, PDB code 2GDV).[35] Thus, the glucose moiety
binds at subsite   1, with Arg209 (O2), His309 (O3),
Asp63 (O4, O6) and His101 (O6), making polar links
to the glucose hydroxyls, as previously described in
that complex and other sucrose related complexes
(Figure 4A).[23b]
An inspection of the modeled conformers showed
that the open cavity defined by the R148A mutation
delineates a long tunnel in which the phloretin moiety
is allocated through hydrophobic interactions of the
triphenolic ring, which is sandwiched between His358,
on one side, and Phe171 and Tyr215, on the other
(Figure 4B). Thus, main differences observed among
the different solutions obtained from the docking
analysis are found in the position of the terminal
phenolic ring, which can adopt different orientations,
possibly through stacking to Phe146 side-chain, which
is located at the beginning of the flexible loop Lys144-
Tyr153.
Figure 3. Chemical structures of the two major phloretin gluco-
sides obtained. (1) Phloretin 4’-O-α-D-glucopyranoside, for the
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In conclusion, docking simulations predict an
efficient α-glycosylation of the phloretin molecule at
para- position (4’-), with a rather constrained location
of the triphenol moiety of the acceptor, which is more
accessible to the catalytic pocket by removal of the
bulky Arg148 side-chain.
Effect of Glucosylation on Phloretin Solubility
Glycosylation is a practical approach to increase the
solubility (and thus the bioavailability) of lipophilic
polyphenols.[36] In particular, we reported the synthesis
of pterostilbene α-monoglucoside using a cyclodextrin
glucosyltransferase (CGTase) from Thermoanaero-
bacter sp.[37] Although the pterostilbene is almost
insoluble in water, the glucosylated derivative dis-
played a solubility of 98�2 mg/L. In this context, the
anomeric configuration of the glycosyl moiety may
exert a notable influence on the solubility properties.
We demonstrated that α-glucosylation of resveratrol
increased its solubility 65-fold, whereas β-glucosyla-
tion in the same position (piceid) was only 12-fold
more soluble.[38] This effect on solubility had also an
impact on the surfactant activity of such compounds.
In the present work, we analyzed the solubility of
phloretin and its glucosides, at 25 °C. The concen-
tration of each compound after 72 h is summarized in
Table 1. Interestingly, the α-monoglucosylation caused
a 71-fold increase in the aqueous solubility of
phloretin. The effect of diglucosylation was even more
pronounced (1200-fold increase). In contrast, in the
presence of 10% (v/v) acetone, the solubility of
phloretin was only ten times higher than in water.
Effect of Glucosylation on Antioxidant Properties
The antioxidant activity of the α-glucosides obtained
from phloretin was analyzed with two different
methods (using ABTS*+ and DPPH as radicals) and
compared with the aglycon. Figure 5 shows the Trolox
Equivalent Antioxidant Capacity (TEAC) values of the
phloretin and its glucosides. A value lower than 1
means that the compound possesses more antioxidant
capacity than Trolox on ABTS*+ (Figure 5A) or DPPH
(Figure 5B) reduction.
As shown in Figure 5, the α-glucosylation decreases
the antioxidant capacity of phloretin with a statistically
significant difference. This effect was expected since
the antioxidant mechanism of polyphenols is related to
the presence of OH groups that can donate a hydrogen
to another compound. The decrease upon glucosylation
has been observed with related compounds such as
resveratrol.[38] However, the loss of antioxidant ca-
pacity is not very large and initial activity could be
recovered upon deglycosylation in vivo.[39]
Figure 4. Docking simulation of mono-glucosylated phloretin
into the TtSPP_R134A mutant. (A) Interactions of a representa-
tive conformer of the first-ranked cluster in the catalytic pocket
of TtSPP, as a result of the final docking simulation from
AutoDock Vina. The catalytic residues are shown in purple, and
residues defined as flexible are represented in grey, except the
catalytic Glu252. (B) The residues considered flexible in the
calculation do not move significantly and constrict binding of
the triphenyl moiety of phloretin, allowing mobility only at the
terminal phenyl ring. Two conformers are represented to
highlight the conformational changes observed at the Phe146
side-chain, which modulate the position of the terminal phenyl.











[b] In MOPS (50 mM) at pH 6.5 containing 10% (v/v) of
acetone.
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Effect of Glucosylation on Percutaneous Absorption
Phloretin has great potential in cosmetic application
because of its capacity to protect cells against UV
radiation and/or antimicrobial activity.[27,40] In this
context, we analyzed the percutaneous absorption
using pig skin placed in a vertical diffusion cell as
model (Figure S7, Supplementary Material).[41] The
resulting recovery was acceptable (100�15%) for all
the tested solutions. The amount of compound present
in different skin layers was analyzed by HPLC (Fig-
ure 6). The amounts retained by the stratum corneum
were not absorbed by the skin and do not contribute to
the systemic dose. Percutaneous absorption (Perc. Abs)
is assumed to be the sum of compound amount present
in epidermis, dermis and receptor fluid (Figure S8,
Supplementary Material).
All compounds were detected in all skin layers
except the fluid receptor. Phloretin showed its ability
to penetrate to the innermost layers of the skin
(detected at dermis level) due to its high lipophilicity
(log P>2) and low molecular weight. Glycosylation of
phloretin (monoglucoside) showed a penetration pro-
file similar to phloretin, without significant differences.
Therefore, monoglucoside, even being more hydro-
philic due to derivatization, provides a greater antiox-
idant action in the same skin layers as phloretin. In
addition, the stratum corneum layer can act as a
reservoir, retaining these compounds and maintaining
their antioxidative effect for longer.
However, the diglucoside, with highest molecular
weight and hydrophilicity, is detected mainly in super-
ficial layers. This fact could make the diglucosylated
derivative an interesting compound for cosmetic
applications, which require compounds with moderate
antioxidant capacity and low skin absorption to protect
the skin surface for longer time periods.[42] The higher
solubility of both derivatives provides an advantage for
the preparation of the dermocosmetic formulations.
Conclusion
This article demonstrates that phloretin glucosylation
can be achieved with a high conversion efficiency by
using the phosphorylase mutant TtSPP_R134A. The
glucosylation position of the monoglucoside was
determined by 2D-NMR and the structural features
that determine this specificity were deciphered by a
docking model. A novel phloretin diglucoside was
synthesized, in which the glucoses are bound by an
unusual α(1!3) linkage. Although the synthetized
glucosides display less antioxidant activity compared
with the aglycon, their greater aqueous solubility could
increase the bioavailability. In addition, the diglucoside
showed a lower skin penetrability, which could be
useful for cosmetic preparations due to its capacity to
protect external skin layers over a prolonged time.
Glycosylation of phloretin could become a strategy to
obtain a prodrug for pharmaceutical preparations with
a better uptake compared to the aglycon.
Figure 5. Antioxidant effect of phloretin and its glucosides on
(A) ABTS*+ reduction and (B) DPPH reduction. In the assay,
Trolox was used as reference. Data is expressed as TEAC
value�SD (n=3, # indicates p<0.025 vs. phloretin).
Figure 6. Skin distribution of phloretin, its monoglucoside (1)
and diglucoside (2) within the different skin layers. W is the
surface excess, SC is the stratum corneum, E is the epidermis,
D is the dermis, FR is the fluid receptor and Perc. Abs. is the
percutaneous absorption. The results were expressed as μg/cm2
(mean values� standard deviations, n=3, *p<0.05) of Active
Pharmaceutical Ingredient (API).
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Experimental Section
Materials
Phloretin was purchased from Hunan MT Health Inc. (Hunan,
China). Sucrose was obtained from Scharlau. BCA (2,2-
Biquinoline-4,4-dicarboxylic acid dipotassium salt trihydrate),
ABTS [2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic
acid)], DPPH (2,2-diphenyl-1-picrylhydrazyl) and (R)-Trolox
(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) were
acquired from Sigma Aldrich. All other reagents and solvents
were of the highest purity grade available.
Enzyme Production
For the production of recombinant sucrose phosphorylase
mutant TtSPP_R134A from Thermoanaerobacterium thermo-
saccharolyticum, the encoding gene was ligated into the
expression plasmid pCXshP34 as described in previous
works.[33] Next, the plasmid was transformed into E. coli BL21
cells. To produce the enzyme, the cells were grown at 37 °C
(with continuous shaking at 200 rpm) in 5 mL of LB medium
with 5 μL of ampicillin (100 mg/mL) during 8 h. Next, the
preculture was added to 500 mL of LB medium contained in a
2 L Erlenmeyer flask with 500 μL of ampicillin. The culture
was grown overnight at 37 °C with continuous shaking at
200 rpm. Subsequently, the cells were centrifuged at
10,000 rpm and 4 °C during 15 min, and the cell pellet was
frozen at   20 °C. To extract the enzyme from the cells, the
frozen cell pellet was slowly thawed on ice, and the cells were
suspended in lysis buffer, containing lysozyme (1 mg/mL) and
1% of 10 mM phenylmethanesulfonyl fluoride (PMSF) in
50 mM MOPS buffer at pH 6.5. The suspended cells were
subsequently disrupted by sonication (Branson 250 Sonifier,
level 3, 50% duty cycle) 3 times during 3 min each cycle. The
cell debris was removed by centrifugation for 30 min at
4,000 rpm and 4 °C, and the supernatant (crude cell extract)
containing the enzyme was collected. The enzyme was semi-
purified using heat purification, by incubating the crude cell
extract in a water bath at 60 °C during 30 min. After this step,
the mixture was centrifuged at 4,000×g during 30 min and the
supernatant was recovered and stored at 4 °C.
BCA Assay for Protein Concentration
The protein concentration was determined using the Pierce™
BCA Protein Assay Kit (Thermo Fisher Scientific), following
the manufacturer’s instructions. For the calibration curves,
bovine serum albumin standard (BSA) solution was provided
with the kit.
Assay for Enzyme Activity
The sucrose phosphorylase activity was evaluated by the
bicinchoninic acid (BCA) assay for reducing sugars described
by Waffenschmidt et al. with some modifications.[43] This assay
was adapted to a 96-well microplate scale. The BCA solution
was prepared as a mixture of stock solutions A, B and ethanol
(100%) in the ratio 23:1:6. Stock solution A contained 1.56 g/L
of 4,4’-dicarboxy-2,2’-biquinoline dipotassium salt (Sigma-
Aldrich) and 62.3 g/L of anhydrous Na2CO3 (Fluka). Stock
solution B was composed out of 3.5 g aspartic acid (Sigma-
Aldrich) and 5 g of anhydrous Na2CO3 (Fluka) dissolved in
100 mL of ultra-pure water, which was subsequently mixed
with 1.09 g of CuSO4 (Riedel-de Haën) dissolved in 40 mL of
ultra-pure water. Additional water was then added to a total
volume of 150 mL for the final B solution. A calibration
standard curve of fructose between 0 and 250 μM was made.
The reaction mixture (1 mL) contained 200 mM phosphate and
100 mM sucrose in 50 mM MOPS buffer (pH 6.5). The enzyme
(10 μL) was conveniently diluted to fit into the calibration
curve. The incubation was at 55 °C and samples were taken at
different times during 14 min. Aliquots (25 μL) and fructose
standards were added to wells containing 150 μL of BCA
solution. The plate was covered and incubated at 70 °C for
30 min in the dark. The absorbance was measured with a
spectrophotometer (Zenyth 200) at 540 nm. One unit of activity
(1 U) corresponded to the release of one μmol of reducing
sugars per minute.
General Procedure for Phloretin Glucosylation
For the glucosylation reaction, 10 mg of phloretin in 200 μL of
acetone were mixed with 684 mg of sucrose in 1400 μL of
50 mM MOPS buffer (pH 6.5) and 200 μL of sucrose phosphor-
ylase TtSP_R134A (10 U). The total volume was 2 mL. The
reaction was maintained at 48 °C during 24 h with orbital
shaking (800 rpm) and followed by thin-layer chromatography
(TLC) and high-performance liquid chromatography (HPLC).
The TLC analysis was carried out with 60 F254 silica gel plates
(Merck) with a mixture of ethyl acetate, methanol and H2O
(30:5:4) as mobile phase. The plate was revealed under UV
light and using 10% of H2SO4 solution. HPLC analysis was
performed using a quaternary pump (model 600, Waters,
Milford, MA, USA) coupled to an autosampler (model ProStar
420, Varian Inc., Palo Alto, CA, USA). The column was a
Zorbax Eclipse Plus C18 (4.6×100 mm, 3.5 μm, Agilent) at
40 °C and the detector was a photodiode array (ProStar, Varian).
Peaks were detected at 297 nm and analyzed with the software
Varian Star LC workstation 6.41. The mobile phase was
composed of water and acetonitrile, both solvents with 0.2% (v/
v) of formic acid, and the flow rate was 0.8 mL/min. The
gradient started with 15% (v/v) of acetonitrile. The acetonitrile
percentage was increased to 40% (v/v) within 5 min, keeping
this percentage constant during 5 min. After that, the mobile
phase returned to the initial conditions and the column was
equilibrated for 5 min.
Purification of Glucosylated Derivatives of Phlor-
etin
The reaction was scaled up to purify the glucosylated products.
The reaction mixture contained 100 mg of phloretin in 2 mL of
acetone, 6.84 g of sucrose in 17 mL of 50 mM MOPS buffer
(pH 6.5) and sucrose phosphorylase TtSPP_R134A (65 U). The
mixture was kept at 48 °C during 56 h with orbital shaking
(1000 rpm), and the glucosylation progress was followed by
TLC and HPLC as described. When the concentration of the
monoglucoside derivative reached a value of approximately
4.3 mg/mL, the reaction was stopped with methanol (20 mL)
and the solvent evaporated with a rotary evaporator (model R-
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210, Büchi; Flawil, Switzerland). The purification was carried
out using a silica gel 60 (particle size 0.06–0.2 mm, Scharlau)
chromatographic column after extraction steps of phenolic
compounds with 2-butanone (5×20 mL) to remove the residual
sugars. The solutions with suspended silica were evaporated
with the rotary evaporator and the product was adsorbed in the
silica. The mobile phase consisted of a mixture of ethyl acetate,
methanol and water at a ratio of 30:5:4 (v/v/v). The different
fractions were collected in test tubes and the purification was
followed by TLC with the method previously described. Finally,
the solvents were evaporated to obtain the pure products.
Mass Spectrometry (MS)
The molecular weight of purified phloretin glucosides was
determined by mass spectrometry with an electrospray coupled
to a hybrid QTOF analyzer (model QSTAR, Pulsar i, AB Sciex)
in positive reflector mode. Methanol with sodium iodide was
used as the ionizing phase.
Nuclear Magnetic Resonance (NMR) Analysis
The structure of the glucosylated derivatives of phloretin was
determined using a combination of 1D and 2D (COSY, DEPT-
HSQC, NOESY) standard NMR techniques. The spectra of the
samples, dissolved in DMSO-d6 (ca. 7 mM), were recorded on
a Bruker IVDr 600 spectrometer equipped with a BBI probe
with gradients in the Z axis, at a temperature of 300 K.
Chemical shifts were expressed in parts per million (ppm).
Residual DMSO-d5 signal was used as an internal reference
(2.5 ppm). All the employed pulse sequences were provided by
Bruker. For the DEPT-HSQC experiment, values of 8 ppm and
1 K points, for the 1H dimension, and 165 ppm and 256 points
for the 13 C dimension, were used. For the homonuclear COSY
and NOESY experiments, 8 ppm windows were used with a
1 K×256 point matrix. For the NOESY the mixing time was
500 ms.
Phloretin 4’-O-α-D-Glucopyranoside (1)
The compound (1) was obtained as a pinkish powder (58.3 mg,
33%); 1H NMR (CD3OD) δ: 2.86 (2H, m, CH2-β), 3.30 (2H, m,
CH2-α), 3.45 (1H, dd, J=8.94, 9.96 Hz, H4’’), 3.54 (1H, ddd,
J=2.58, 4.38, 9.96 Hz, H5’’), 3.57 (1H, dd, J=3.63, 9.75 Hz,
H2’’), 3.70 (1H, dd, J=4.35, 12.15 Hz, H6’’a), 3.74 (1H, dd,
J=2.58, 12.06 Hz, H6’’b), 3.81 (1H, dd, J=9.09, 9.57 Hz,
H3’’), 5.53 (1H, d, J=3.60 Hz, H1’’), 6.17 (2H, s, H3’/H5’),
6.69 (2H, d, J=8.50 Hz, H2/H6), 7.04 (2H, d, J=8.50 Hz, H3/
H5); 13C NMR (CD3OD) δ: 31.2 (CH2 β), 47.4 (CH2 α), 62.0
(C6’’), 71.0 (C4’’), 73.0 (C2’’), 74.6 (C5’’), 74.8 (C3’’), 96.4
(C3’/C5’), 98.4 (C1’’), 107.0 (C1’), 115.9 (C3/C5), 130.3 (C2/
C6), 133.8 (C1), 156.6 (C4), 164.5 (C4’), 165.7 (C2’/C6’),




Column chromatography on silica gel afforded the compound
(2) as an orange powder (16.2 mg, 6%); 1H NMR (CD3OD) δ:
2.86 (2H, m, CH2-β), 3.30 (2H, m, CH2-α), 3,29 (1H, H4’’’),
3.47 (1H, H2’’’), 3.58 (1H, H5’’), 3,74-3.64 (6H, H3’’’, H2’’,
H4’’, 2H6’’’, H6’’), 3.8 (1H, H6’’), 3.91 (1H, H3’’), 3.96 (1H,
H5’’’), 5.22 (1H, d, J=3.70 Hz, H1’’’), 5.57 (1H, d, J=
3.70 Hz, H1’’), 6.18 (2H, s, H3’/H5’), 6.69 (2H, d, J=8.50 Hz,
H2/H6), 7.04 (2H, d, J=8.50 Hz, H3/H5); HPLC-UV (297 nm):
tR 9.14 min (80%). ESI-MS (m/z) 621.1787 [M+Na]+.
Automated Docking of Different Phloretin Gluco-
sides into TtSPP_R134A Structure
The three putative phloretin monoglucosylated ligands were
built using PyMolX11Hybrid (The PyMOL Molecular Graphics
System, Version 2.0 Schrödinger, LLC).[44] The coordinates of
TtSPP[23b] (PDB code 6S9 V) were modified to R148A mutation
in Coot.[45] R148 residue in crystal structure deposited in the
PDB database corresponds to R134 in wild-type TtSPP
sequence due to 14 residues long N-terminal (histidine) tag. All
other molecules and water found in the crystal were removed,
and this protein was used as a receptor in the docking
simulation. AutodockTools[33] was used to prepare the coordi-
nates and the ligands to create the .pdbqt files. Polar hydrogens
and charges (computed Gasteiger method) were added to the
receptor coordinates, and these coordinates were treated as rigid
side chain residues. The glycosidic linkages between the
glucose and phloretin, and the four C  C bonds linking the two
aromatic rings in the phloretin molecule were defined as
rotatable bonds in the different complexes. Firstly, a grid box
was manually defined to run Autogrid, and Autodock 4.2[33] was
used for a preliminary docking simulation to find the best
phloretin glycosylation position. Autodock 4.2 was executed
with the Lamarkian genetic algorithm, and 25 possible
conformations were calculated for each monoglucoside deriva-
tive. A population size of 150, rate of gene mutation 0.02, and
crossover rate of 0.8 were the standard parameters chosen to
launch the program. Most consistent results were obtained for
the para- derivative (position a) above) of the glucose molecule
in the triphenolic ring, which presents a clearly preferred first
ranked cluster with minimum   7.5 Kcal/mol binding energy
(Figure S6). Therefore, assuming a p-derivative as the main
glucosylated product, AutoDock Vina program[34] was then used
to improve the accuracy of the docking method, and several
residues protruding at the catalytic tunnel, were defined as a
flexible side chain in AutoDock Tools. The grid box around the
catalytic pocket was defined with 30 Å×30 Å×60 Å dimen-
sions. Exhaustiveness was adjusted to 1000 and calculations for
the docking were performed with Lamarckian Genetic Algo-
rithm. Around 20 solutions were calculated in a binding energy
range between   12.6 and   11.6 Kcal/mol. The best solutions
were selected through an energetic and conformational crite-
rion.
Solubility of Phloretin and its Glucosides
Aqueous solutions of phloretin and the corresponding α-gluco-
sides were maintained at 25 °C during 3 days in water at
saturated conditions with orbital stirring. The samples were
centrifuged and the supernatant solution was diluted in
methanol to fit the calibration curve of phloretin (0–200 μg/
mL). Different volumes of 200 μL of each sample were taken
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by triplicate, and the absorbance was measured by UV
spectrophotometry (Tecan Infinite M200) at 297 nm.
Antioxidant Activity
The antioxidant activity was determined with the 2,2-diphenyl-
1-picrylhydrazyl (DPPH) and the 2,2-azino-bis(3-ethylbenzo-
thiazoline-6-sulfonic acid) diammonium salt (ABTS) method,
using Trolox as reference antioxidant compound. The DPPH
and ABTS assays were performed by triplicate in 96-well
plates. The significant differences between the values were
calculated with a t-test comparing the average and their standard
deviations, considering n the number of experiments and
significant differences when p < 0.025.
DPPH assay. A solution of 200 μM of DPPH was made in
methanol. Different dilutions of each antioxidant in methanol
were made depending on the antioxidant capacity. For Trolox,
the maximum concentration was 100 μM. For phloretin and
their glucosides the concentrations were between 0 and 500 μM.
The assay was adapted to a 96-well plate. A volume of 100 μL
of each antioxidant was taken and 200 μL of DPPH solution
was added. The plate was incubated in the dark for 15 min at
room temperature. Next, the absorbance was measured with a
Zenyth 200 spectrophotometer at 540 nm. The EC50 was
defined as the concentration of compound needed to reduce the
DPPH absorbance to 50%. The results were also expressed as
Trolox Equivalent Antioxidant Capacity (TEAC), which corre-
sponds to the concentration of the active compound (μM) that
reduces the absorbance of DPPH the same that 1 μM of Trolox.
The TEAC value was calculated from EC50 of each compound
and EC50 of Trolox.
ABTS assay. The working solution was prepared by mixing
5 ml of ABTS (7 mM) with 5 mL of potassium persulfate
K2S2O8 (2.45 mM) and leaving it in the dark during 16 h at
room temperature to oxidize the ABTS to the cation radical
ABTS*+. Standard solutions with concentrations between 0 and
200 μM for Trolox and between 0 and 1000 μM for phloretin
and its glucosides were prepared in methanol. The antioxidants
(20 μL) at different concentrations were mixed with 230 μL of
ABTS*+ working solution (previously diluted with methanol to
get an absorbance of 0.7 at 655 nm). After incubation in the
dark at room temperature, the absorbance was measured with a
Zenyth 200 spectrophotometer at 655 nm to get the linear
regressions of the antioxidants. The EC50 was referred to the
concentration of compound needed to reduce the ABTS*+
absorbance to 50%. The results were also expressed as Trolox
Equivalent Antioxidant Capacity (TEAC) as described in the
DPPH assay, calculated from EC50 of each compound and
EC50 of Trolox.
Percutaneous Activity Methodology
The in vitro release study was carried out with pig biopsies
placed on Franz static diffusion cells (3 mL, 1.86 cm2 of
exposed area, diameter: 30 mm, Lara-Spiral, Courtenon,
France) in order to determine the compartmental distribution of
Active Pharmaceutical Ingredient (API) after an exposure time
of 24 h. The OECD Guidelines were closely adhered to during
this study.[46] The pig skin, provided by the Department of
Cardiology of the Hospital Clinic (Barcelona, Spain), is
considered morphologically and functionally equivalent to
human skin for percutaneous absorption studies.[47] The
procedure for these studies was described in previous reports.[41]
Ultra-pure water was employed as receptor fluid, and cells were
placed in a thermostated water bath (32 °C) containing a
magnetic stirring device to obtain the skin surface temperature
at 32�1 °C. The integrity of the skin samples was evaluated by
measuring the transepidermal water loss (TEWL) with Tewa-
meter TM300 (Courage & Khazaka, Cologne, Germany)
considering correct TEWL values under 15 gm  2 h  1. Solutions
with active compound (phloretin and its glucosides) were
applied (10.75 μL/cm2) on dermatomized porcine skin biopsies.
Experiments were done by triplicate in three diffusion cells, and
an extra diffusion cell without any active compound was used
as control. After 24 h, the skin surface was washed to recover
the excess of compounds (W). Then, the receptor fluid (RF)
was recovered, and stripping procedures were performed on the
surface horny layers of the stratum corneum (SC) with adhesive
tape (D-squame, Cuderm Corporation, Dallas, USA). Eight
strips were employed in order to remove most of the amount of
substance contained in the stratum corneum. The viable
epidermis (E) was separated from the dermis (D) after heat
treatment. The different samples to be analyzed (W, RF, SC, E
and D) were extracted and/or diluted in methanol (Merck,
Darmstadt, Germany). The phloretin and the corresponding
glucosides concentrations were analyzed by HPLC, as previ-
ously described. The substance is considered absorbed when is
present in epidermis (except for the stratum corneum), dermis
and receptor fluid. The amounts founded in the stratum
corneum are not considered to be percutaneously absorbed.[46c]
The results are shown as mean values (expressed as μg/cm2)�
standard deviations. The Kruskal-Wallis test was applied for
group comparisons, with the software STATGRAPHICS
®
,
assuming significant differences when p < 0.05.
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